Endo International PLC (NASDAQ:ENDP) (TSE:ENL) – Investment analysts at Gabelli dropped their FY2018 earnings per share estimates for shares of Endo International PLC in a research note issued to investors on Friday. Gabelli analyst K. Kedra now forecasts that the company will post earnings of $3.05 per share for the year, down from their previous forecast of $3.15. Gabelli also issued estimates for Endo International PLC’s FY2019 earnings at $3.20 EPS.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.06. Endo International PLC had a positive return on equity of 66.98% and a negative net margin of 126.97%. The company had revenue of $786.90 million for the quarter, compared to analyst estimates of $794.93 million. During the same period in the prior year, the company posted $1.01 EPS. Endo International PLC’s quarterly revenue was down 11.0% on a year-over-year basis.
TRADEMARK VIOLATION NOTICE: This report was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.chaffeybreeze.com/2017/11/13/brokers-issue-forecasts-for-endo-international-plcs-fy2018-earnings-endp.html.
A number of other equities analysts have also issued reports on the company. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Endo International PLC in a research report on Sunday, July 23rd. ValuEngine lowered Endo International PLC from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Zacks Investment Research raised Endo International PLC from a “hold” rating to a “buy” rating and set a $9.75 target price on the stock in a research report on Wednesday, October 11th. Royal Bank Of Canada set a $9.00 price target on Endo International PLC and gave the company a “hold” rating in a research report on Tuesday, October 17th. Finally, BidaskClub raised Endo International PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and five have assigned a buy rating to the stock. Endo International PLC has an average rating of “Hold” and an average target price of $11.67.
Endo International PLC (NASDAQ:ENDP) opened at $6.93 on Monday. Endo International PLC has a 52-week low of $5.77 and a 52-week high of $18.63. The stock has a market capitalization of $1,547.56, a P/E ratio of 1.43 and a beta of 0.53. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86.
Large investors have recently added to or reduced their stakes in the company. James Investment Research Inc. bought a new position in shares of Endo International PLC in the second quarter worth $113,000. Blair William & Co. IL bought a new position in shares of Endo International PLC in the second quarter worth $126,000. Point View Wealth Management Inc. boosted its stake in Endo International PLC by 16.6% during the second quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock valued at $149,000 after buying an additional 1,900 shares in the last quarter. Riverhead Capital Management LLC boosted its stake in Endo International PLC by 64.4% during the second quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after buying an additional 5,887 shares in the last quarter. Finally, Bank of Hawaii bought a new position in Endo International PLC during the second quarter valued at about $180,000. 90.50% of the stock is owned by institutional investors.
In other Endo International PLC news, CFO Blaise Coleman purchased 6,500 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The stock was bought at an average price of $7.89 per share, with a total value of $51,285.00. Following the completion of the purchase, the chief financial officer now owns 13,729 shares in the company, valued at approximately $108,321.81. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.50% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.